Navigation Links
Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
Date:5/21/2008

ing provided under a collaborative agreement between Romark and F. Hoffmann-La Roche Ltd.

Romark recently announced enrollment for its STEALTH C-3 clinical trial, a Phase II randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alfa-2a and ribavirin in treatment nave patients with chronic hepatitis C infected with genotype 1. Enrollment for the STEALTH C-3 study began in April 2008 and the trial will enroll 60 patients at 15 centers in the U.S.

The primary objective of STEALTH C-3 is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo.

About Nitazoxanide

Nitazoxanide belongs to a new class of small molecule kinase activators called the thiazolides. Like interferons, thiazolides modulate cell signaling pathways involved in the host cell's innate defense against viruses. Thiazolides can be administered orally and are not associated with side effects commonly associated with use of interferon. Nitazoxanide was discovered by Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark, and was initially developed by Romark and approved for marketing in the United States as a treatment for cryptosporidiosis. Recent laboratory studies have shown that nitazoxanide does not induce resistance mediated by mutations in the viral genome.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood. A large majority of those infected do not show symptoms, but fatigue, abdominal pa
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
2. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
3. Romark Laboratories Raises $18 Million in Institutional Financing
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
6. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
7. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
8. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
9. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
10. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... RIVIERA BEACH, Fla., Dec. 14 Perry ... 40 years, announces the launch of the Sigma ... advanced technology of the Sigma Elite is available ... www.perrybaromedical.com ) and has a Patent Pending. ,, ... ,, Data Capture Via Computerized System for ...
(Date:12/14/2009)... Dec. 14 Greenway Medical Technologies, ... EHR, Prime Suite (®) 2011, ... Ambulatory EHR, additionally certified for Child Health ... Greenway,s Prime Suite 2011 achieved the ... designations offered by the Certification Commission for ...
(Date:12/14/2009)... Conn., ,Dec. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, ... that it had received a complete response letter ... related to its New Drug Application ("NDA") for ... The letter indicates that the FDA cannot approve ... provides recommendations to address remaining issues. ,, Alan ...
Breaking Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 3Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 4Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Study supports validity of test that indicates widespread unconscious bias 49273 1Study supports validity of test that indicates widespread unconscious bias 49273 2Roux en Y weight loss surgery raises kidney stone risk 49271 1Roux en Y weight loss surgery raises kidney stone risk 49271 2Critical Information Network 28CiNet 28TM 29 29 Launches to Provide eLearning Solutions to Public Safety Healthcare and Industrial Operations Profes 49270 1Critical Information Network 28CiNet 28TM 29 29 Launches to Provide eLearning Solutions to Public Safety Healthcare and Industrial Operations Profes 49270 2Critical Information Network 28CiNet 28TM 29 29 Launches to Provide eLearning Solutions to Public Safety Healthcare and Industrial Operations Profes 49270 3
(Date:12/14/2009)... Dec. 15 In today,s academic medical ... than ever. Now the University HealthSystem Consortium (UHC) ... Value Analysis: Achieving Cost Efficiencies in Health Care, ... complex environments. These new materials, developed with the ... provide a practical guide to planning, implementing, and ...
(Date:12/14/2009)... PARK, Ill. and HOLLYWOOD, Fla., Dec. 14 ... ) announced today a definitive agreement to ... ), a leading provider of laboratory information ... cash. ,, The acquisition strengthens Abbott,s ... providing advanced web-based applications to help laboratories ...
(Date:12/14/2009)... -- Aflac Incorporated announced today that it has ... notes with a coupon of 6.9%. The notes ... to yield 6.984%. The company anticipates using the ... general corporate purposes. ,, Commenting on the pricing ... Chief Financial Officer Kriss Cloninger III commented: "This ...
(Date:12/14/2009)... variants seen in one gene, researchers say , , MONDAY, ... a dozen genetic variants in a single gene linked ... School of Medicine in St. Louis analyzed the DNA ... failure, and identified 129 variants in four genes that ... 1,117 whites with heart failure and 625 healthy whites ...
(Date:12/14/2009)... doses from common CT procedures vary widely and are higher than ... a new study led by University of California, San Francisco ... ... (Vocus) December 14, 2009 -- Radiation doses from common CT procedures ... increased risk for cancer, according to a new study led by ...
Breaking Medicine News(10 mins):Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5
... with the healthcare system is that despite increased salaries family ... complain// that it takes days to get an appointment fixed. ... guarantee good medical attention out of hours. But some GPs ... work perfectly in the past. But the problem is that ...
... that calcium supplementation reduces risk of bone fractures in older ... a new study has found// . The greatest challenge therefore ... the researchers. , ,The researchers recruited nearly 1,460 ... to determine their compliance rates associated with intake of calcium ...
... is doubly beneficial, for it ensures two things – one, ... cleaner //(Lady of the House!) Women, spoke of being in ... order, but the flip side to it, is that nearly ... obsessive that they could be called “Cleanoholics” ! ,Women ...
... become the benchmark against which the growth of babies will ... the practice of almost 4 decades, //where babies have always ... pattern portrayed by formula- fed babies. ,It is ... as compared to breast fed infants and this makes them ...
... medical charity in the UK it is found that ... healthcare officials. //The Government though has taken all possible ... reforms. But the sad state is that UK lags ... This Picker Institute study report criticizes the present prevailing ...
... has banned chronic snorers from joining up. These are new ... chronic snorers' sounds disturb the life of others, a new ... army official Li Chunming as saying. ,The People's Liberation ... soldiers. It has also decided to ban people who wear ...
Other Medicine News:Health News:Women Fail to Take Calcium Pills Regularly; High Risk of Bone Fractures 2
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... range from 2ul to 5000ul. Fills and ... prevents inadvertent volume change. Novel hand grip ... is autoclavable at 121C(250F). To prevent corrosion ... for one-handed operation. Auto or Normal trigger ...
... adjustable, air-displacement pipette with a patented multifunctional ... of the Pipetman family, sharing many of ... We also added a number of features ... models cover the full range of volumes ...
Medicine Products: